Granite Point Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Granite Point Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-12,000	Closed	-$297K	–	78
2014 Q3	$297K	Hold	12,000	–	–	0.15%	75
2014 Q2	$271K	Sell	12,000 -4,400	-27%	-$91.9K	0.19%	79
2014 Q1	$399K	Sell	16,400 -8,600	-34%	-$218K	0.29%	86
2013 Q4	$625K	Buy	+25,000	New	+$590K	0.1%	81

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Granite Point Capital Management's ACAD Position: Q4 2014 in Review

Granite Point Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2014, closing a stake of 12,000 shares — an estimated $297K sold.

Granite Point Capital Management first reported a position in ACAD in Q4 2013 and held it in 4 quarters. The position peaked at $625K in Q4 2013. 182 funds tracked by Wall St. Rank hold ACAD as of Q4 2014.

Granite Point Capital Management reported no remaining Acadia Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
Granite Point Capital Management sold 12,000 Acadia Pharmaceuticals shares in Q4 2014, an estimated $297K.
Granite Point Capital Management first reported a position in Acadia Pharmaceuticals in Q4 2013 and held it in 4 quarters.
Granite Point Capital Management's Acadia Pharmaceuticals position peaked at $625K in Q4 2013.
182 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2014.

Based on Granite Point Capital Management's 13F filing for Q4 2014, filed 13 Feb 2015.